CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Argiriadi, M.A., Benatuil, L., Dubrovska, I., Egan, D.A., Gao, L., Greischar, A., Hardman, J., Harlan, J., Iyer, R.B., Judge, R.A., Lake, M., Perron, D.C., Sadhukhan, R., Sielaff, B., Sousa, S., Wang, R., McRae, B.L.(2019) BMC Mol Cell Biol 20: 29-29
- PubMed: 31382872 
- DOI: https://doi.org/10.1186/s12860-019-0213-4
- Primary Citation of Related Structures:  
6PE7, 6PE8, 6PE9 - PubMed Abstract: 
CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications.
Organizational Affiliation: 
AbbVie Bioresearch Center, 381 Plantation Street, Worcester, MA, 01605, USA. maria.argiriadi@abbvie.com.